Latest news newssearch boxGO All Ad hoc Other 04 Apr 2022 The Journal of Neurosurgery reports impact of clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage 10 Mar 2022 New data for daridorexant in patients with insomnia disorder – including long-term safety and efficacy – to be presented at World Sleep 2022 03 Mar 2022 Idorsia issues Notice of the 2022 Annual General Meeting of Shareholders 25 Feb 2022 QUVIVIQ (daridorexant) recommended for approval in Europe as a new treatment for adults with insomnia disorder 08 Feb 2022 Idorsia announces financial results for 2021 – 2022 to be a transformative year – Sustainable profitability expected in 2025 26 Jan 2022 Idorsia expands its commercialization partnership with Syneos Health for daridorexant in Europe and Canada 24 Jan 2022 Idorsia appoints Guy Braunstein to Chief Medical Officer and Alberto Gimona to Head of Global Clinical Development 20 Jan 2022 Idorsia receives Japanese PMDA approval of PIVLAZ (clazosentan sodium) 150 mg 20 Jan 2022 The Lancet Neurology reports impact of daridorexant on both nighttime symptoms and daytime functioning in adults with insomnia 12 Jan 2022 Jennifer Aniston partners with Idorsia U.S. to launch ‘Seize the Night & Day’ campaign inspiring Americans to understand their relationship with sleep 10 Jan 2022 Idorsia presents at the 40th J.P. Morgan Healthcare Conference – Ready for first product launches – QUVIVIQ (daridorexant) approved by the US FDA 10 Jan 2022 Idorsia receives US FDA approval of QUVIVIQ (daridorexant) 25 and 50 mg for the treatment of adults with insomnia 13 Dec 2021 Idorsia to further characterize lucerastat for the treatment of Fabry disease by continuing the open-label extension of the Phase 3 MODIFY study 01 Nov 2021 Idorsia to advance cenerimod into Phase 3 development for treatment of patients with systemic lupus erythematosus 27 Oct 2021 Johnson & Johnson partially converts its convertible loan 26 Oct 2021 Idorsia announces financial results for the third quarter 2021 – company progressing and launch preparations in key markets well underway 11 Oct 2021 Idorsia announces the results of MODIFY, a Phase 3 study of lucerastat in Fabry disease 29 Jul 2021 Application of Jean-Paul and Martine Clozel regarding the exemption from the offer obligation in relation to Idorsia Ltd 28 Jul 2021 Idorsia announces the reference share price and the initial conversion price of convertible bonds successfully placed today 28 Jul 2021 Idorsia successfully completes the offering of convertible bonds, securing funding to develop the company into a leading biopharmaceutical company 1 2 3 4 5 6 7 8